Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT03632798IIIRecurrent ovarian cancerAvastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Platinum-Resistant or -Sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerMS, WVView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitorApproved in Other Cancers
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
NCT03940196IIIRecurrent ovarian cancer (<3 prior therapies for platinum resistant disease)ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian CancerAZ, CA, CO, FL, GA, IL, IA, KY, MD, MA, MN, MO, NE, NV, NJ, NC, OH, OR, PA, RI, SD, TX, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
TTfieldsNovoTTF-100L(O)Microtubule destabilizer/mitotic inhibitorClinical Trials
NCT02312245IIRecurrent ovarian cancerAvatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube CancersAZ, FL, MNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
NCT02873962IIPartially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients have to be BRCA WT and have no prior PARP inhibitor)A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal CancerMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RucaparibRubraca, CO-338, PF 01367338, AG-014699PARP inhibitorApproved in Ovarian Cancer
NCT01851369IIGranulosa cell ovarian cancerA Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and LymphomasMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MethoxyamineTRC102Base excision repair inhibitorClinical Trials
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agentApproved in Other Cancers
NCT02843165IIAdvanced solid tumors with lesion treatable with radiation therapyRandomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic DiseaseCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyRadiotherapy, Irradiation
NCT03428802IIAdvanced solid tumors with POLE, POLD, or BRCA1/2 mutationsA Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic InstabilityNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03462342IIPlatinum sensitive high grade serous ovarian cancer (cohort A), or platinum sensitive BRCA MUT or HRD+ ovarian cancer w/ clinical benefit of PARPi therapy followed by progression in most recent prior regimen (cohort DII)Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian CancerMD, MA, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03570619IIAdvanced solid tumors with CDK12 alterationsIMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsCA, FL, MD, MI, MO, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03651271IIRecurrent ovarian cancer with dMMR, high MSI or high TMBAn Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic CancerCA, NY, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03682289IIAdvanced solid tumors with ARID1A (except clear cell) or ATM alterationsPhase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor MalignanciesCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03693014IIAdvanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatmentA Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint BlockadeCT, NJ, NY, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyRadiotherapy, Irradiation
NCT03732950IIRecurrent ovarian cancerA Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression ProfilingCA, MNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03734692IIPlatinum sensitive ovarian cancer with first or second recurrence in peritoneal cavitySystemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian CancerPAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RintatolimodAtvogenTLR3 agonist and immune cell stimulatorApproved in Other Indications
NCT03673124IIRecurrent low grade serous ovarian cancerA Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or PeritoneumCA, FL, GA, IL, IN, MI, MN, NH, NJ, NM, OH, OK, PA, RI, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LetrozoleFemaraAromatase inhibitorNCCN Guidelines for Ovarian Cancer
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitorApproved in Other Cancers
NCT03797326IIAdvanced solid tumorsA Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)CA, FL, NJ, NY, ND, PA, SD, TN, TX, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LenvatinibMK-7902, Lenvima, ER-203492-00, E7080Multi-targeted RTK inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03868423IIAdvanced solid tumors with ALK or ROS1 activating genomic aberrationsPhase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 OncogenesOHView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BrigatinibAP26113, AlunbrigALK and EGFR kinase inhibitorApproved in Other Cancers
NCT03697304IIAdvanced solid tumors with prior anti-PD-1/PD-L1 AbAn Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic TherapyCA, FL, IN, KY, OK, TN, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BI 754111Blocks LAG-3 inhibition of T cellsClinical Trials
BI 836880anti-VEGF/ANG2 nanobody BI 836880VEGF and Angiopoietin 2 antagonistClinical Trials
Ezabenlimabanti-PD-1 monoclonal antibody BI 754091, BI 754091Blocks PD-L1/2 inhibition of T cellsClinical Trials
NCT03878849IIRecurrent ovarian cancerPhase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®MAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
StenoparibPARP/Tankyrase inhibitor 2X-121, E7449, 2X-121PARP inhibitorClinical Trials
NCT03909152IIRecurrent PR+ low grade serous or granulosa cell ovarian cancerBasket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor), Alone or In Combination With Anastrozole in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial CancerNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AnastrozoleArimidexAromatase inhibitor
Onapristone ERextended-release onapristone, ONA-XRPR antagonist that blocks PR activation and the associated expression of PR-responsive genes
NCT03911557IIAdvanced solid tumors with moderate/high TMBPhase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid TumorsKYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cellsClinical Trials
NCT03907475IIAdvanced solid tumors (with tumor amenable to skin biopsy)DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid TumorsMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CapecitabineXeloda, CAPERNA processing and thymidylate synthase inhibitorNCCN Guidelines for Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitorNCCN Guidelines for Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT02710253IIAdvanced solid tumors with progression on prior immunotherapy or cellular therapy (amenable to radiation therapy)Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic ImmunotherapyTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Radiation TherapyRadiotherapy, Irradiation
NCT03449108IIRecurrent high grade ovarian cancer or carcinosarcomaClinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinProleukinIL-2 receptor agonistApproved in Other Cancers
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
LN-145-S1Autologous Tumor Infiltrating Lymphocytes LN-145-S1, PD-1 selected TIL therapyImmune response against tumor-associated antigensClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03994796IIAdvanced solid tumors with brain metastases and NTRK, ROS1, CDK pathway or PI3K pathway alterationsGenomically-Guided Treatment Trial in Brain MetastasesAK, AZ, AR, CA, CO, CT, FL, GA, ID, IL, IA, KS, KY, LA, MA, MI, MN, MS, MO, MT, NE, NH, NJ, NM, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
PaxalisibGDC-0084, PI3K inhibitor GDC-0084, RG7666PI3K/mTOR inhibitorClinical Trials
NCT04083976IIAdvanced solid tumors with FGFR mutations or fusionsA Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene AlterationsAZ, CO, FL, GA, ME, MA, NJ, NY, NC, OH, PA, TN, TX, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Erdafitinibpan-FGFR tyrosine kinase inhibitor JNJ-42756493pan-FGFR kinase inhibitorApproved in Other Cancers
NCT04171700IIAdvanced solid tumors with mutations in BARD1, BRIP1, FANCA, NBN, RAD51, RAD51B, RAD51C or RAD51D, no prior PARP inhibitorA Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair GenesCA, FL, IL, IA, MA, MN, NY, OH, OK, PA, TN, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RucaparibRubraca, CO-338, PF 01367338, AG-014699PARP inhibitorApproved in Ovarian Cancer
NCT04383210IIAdvanced solid tumors with a NRG1 gene fusionCRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid TumorsAL, AZ, CA, CO, DC, FL, GA, IL, MA, MI, MN, MO, NY, NC, OH, OR, TN, TX, UT, VA, WA, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
SeribantumabSAR256212, MM-121ERBB3 antagonistClinical Trials
NCT04393454IIAdvanced solid tumors with dMMR, after prior immunotherapyPhase II Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After ImmunotherapyNYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
SirolimusRapamycin, RapamunemTOR inhibitorApproved in Other Indications
NCT04469764IIRecurrent ovarian cancer with CCND1-3 or CDK4/6 AMP or CDKN2A alterationsAn Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial CancerCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
AnastrozoleArimidexAromatase inhibitor
LetrozoleFemaraAromatase inhibitorNCCN Guidelines for Ovarian Cancer
NCT04482309IIAdvanced HER2+ solid tumorsA Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)CA, IL, IN, MA, NJ, NY, NC, TN, TX, VA, WAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Trastuzumab deruxtecanT-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201aADC: anti-HER2 + topoisomerase I inhibitor (Dxd)Approved in Other Cancers
NCT04534283IIAdvanced solid tumors with alterations in BRAF, RAF1, MEK1/2, ERK1/2 or NF1A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.INView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
TemuterkibLY3214996ERK inhibitorClinical Trials
NCT04550494IIAdvanced solid tumors with alterations in ARID1A, ATM, ATR, BAP1, BARD1, BRCA 1/2, BRIP1, CDK12, CHK1/2, FANCA/B/C/D2/E/F/G/I/J/L/M/N, IDH1/2, MRE11A, NBN, PALB2, RAD50/51/51B/51C/51D or RAD54L (only 1 prior platinum therapy; gBRCA MUT patients must have progressed on prior PARP inhibitor)A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage ResponseMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
NCT04564027IIAdvanced solid tumors with ATM mutationsA Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)CA, FL, IN, LA, MD, MI, NV, NY, PA, SCView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
NCT04592653IIRecurrent ovarian cancerClinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Nemvaleukin alfaALKS4230, Nemvaleukin, intermediate-affinity interleukin-2 receptor agonist ALKS 4230IL-2R beta and gamma agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04589845IIAdvanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, MDM2, NTRK1/2/3, PIK3CA (multiple mutations), ROS1 or with high TMBTumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform TrialAL, AZ, CA, CO, DE, FL, GA, ID, IL, IN, ME, MD, MI, MN, MO, MT, NV, NH, NJ, NM, NY, NC, OH, OR, PA, SC, TN, TX, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AlectinibAF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802ALK kinase inhibitorApproved in Other Cancers
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
IdasanutlinRO5503781, RG7388, MDM2 antagonist RO5503781MDM2 antagonist
InavolisibRG6114, GDC-0077PI3K alpha inhibitorClinical Trials
IpatasertibGDC-0068, Akt Inhibitor GDC-0068, RG7440pan-AKT inhibitorClinical Trials
Trastuzumab emtansinetrastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansineADC: anti-HER2 + microtubule destabilizer (DM1)Approved in Other Cancers
NCT04625270IIRecurrent low grade serous ovarian cancerA Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)AZ, CA, CT, FL, IL, MN, MO, NV, NM, NY, OH, OK, OR, TN, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DefactinibVS-6063, PF-04554878, PF-04554878FAK inhibitorClinical Trials
VS-6766CKI27, RO5126766, Raf/MEK dual kinase inhibitor RO5126766, CH5126766RAF and MEK inhibitorClinical Trials
NCT04632992IIAdvanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, PIK3CA, PTEN, RET, ROS1 or with high TMB or high MSIMyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseAL, AK, AZ, CA, CT, FL, ID, LA, MD, MI, MO, MT, NE, NJ, NY, OH, OR, TN, TX, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AlectinibAF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802ALK kinase inhibitorApproved in Other Cancers
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
CapecitabineXeloda, CAPERNA processing and thymidylate synthase inhibitorNCCN Guidelines for Ovarian Cancer
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
InavolisibRG6114, GDC-0077PI3K alpha inhibitorClinical Trials
IpatasertibGDC-0068, Akt Inhibitor GDC-0068, RG7440pan-AKT inhibitorClinical Trials
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
PertuzumabPerjeta, monoclonal antibody 2C4, rhuMAb2C4HER2 dimerization inhibitorApproved in Other Cancers
PralsetinibBLU-667RET-kinase inhibitorApproved in Other Cancers
TiragolumabMTIG7192A, RO7092284Blocks TIGIT binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cellsClinical Trials
TrastuzumabHerceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal AntibodyHER2 antagonistApproved in Other Cancers
Trastuzumab emtansinetrastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansineADC: anti-HER2 + microtubule destabilizer (DM1)Approved in Other Cancers
TucatinibIrbinitinib, ONT-380HER2 kinase inhibitorApproved in Other Cancers
NCT04729348IIAdvanced solid tumors with leptomeningeal metastasesPhase II Trial of Pembrolizumab and Lenvatinib for Leptomeningeal MetastasesMAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LenvatinibMK-7902, Lenvima, ER-203492-00, E7080Multi-targeted RTK inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04739618IIAdvanced solid tumors - intratumoral injectionA Phase 2 Trial of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy in Patients With Metastatic Solid CancerAZView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
ThermotherapyClinical Trials
NCT04771520IIAdvanced solid tumors with c-Kit or PDGFRA mutations (except c-KIT V654A or T670I)Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid TumorsTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvapritinibPDGFRa and c-Kit inhibitorApproved in Other Cancers
NCT02896335IIPatients with progressive brain metastases with amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2AA Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK PathwayMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
NCT04189445IIAdvanced solid tumors with FGFR1-4 alterationsA PHASE 2 STUDY OF FUTIBATINIB IN PATIENTS WITH SPECIFIC FGFR ABERRATIONSAZ, CA, IL, IA, MD, MA, MI, OK, PA, TX, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
FutibatinibFGFR inhibitor TAS-120, TAS-120FGFR1-4 inhibitorClinical Trials
NCT04919629IIRecurrent ovarian cancer with symptomatic ascites or pleural effusionRandomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant EffusionNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
APL-2C3-targeted complement inhibitor APL-2Blocks the cleavage of C3Approved in Other Indications
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04957615IIAdvanced solid tumors with ARID1A mutationsA Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid TumorsTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04983745IIAdvanced solid tumors with somatic mutations in ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCI/L, PALB2, PPP2R2A, RAD51B/C/D or RAD54LA Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients With Somatic Homologous Recombination Deficient Advanced or Metastatic CancerTNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DostarlimabTSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT05041257IIPlatinum sensitive FRalpha+ high grade serous ovarian cancer with ≥2 prior platinum regimens, not eligible for further platinum therapy; BRCA MUT patients must have had prior PARP inhibitor therapyA Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)NJView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Mirvetuximab soravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)Clinical Trials
NCT05064280IIAdvanced solid tumors with brain metastasesPhase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LenvatinibMK-7902, Lenvima, ER-203492-00, E7080Multi-targeted RTK inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04669002IIHigh grade ovarian cancer with primary platinum resistance or with stable disease after first-line therapy with no prior PARP inhibitor or high grade ovarian cancer with prior PARP inhibitor maintenance as most recent therapyPhase 2 Study to Evaluate the Safety & Efficacy of EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Patients Who Have: Cohort 1 - Platinum Resistant Disease & Are PARP Inhibitor naïve; Cohort 2 - Had at Least 1 Prior Line of Therapy Which Must Include at Least 1 Line of Platinum-based Chemotherapy Followed by PARP Inhibitor MaintenanceFL, GA, NY, PA, TN, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
EP0057IT-101, cyclodextrin-based polymer-camptothecin CRLX101, camptothecin-polymer conjugate IT-101, CRLX101, NLG207Topoisomerase I inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT04332653Ib/IIaAdvanced solid tumorsAn Open-label Phase 1b/2a Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid TumorsFL, MI, MO, NC, PA, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Efineptakin alfarecombinant human IL-7-hybrid Fc NT-I7, Hyleukin, GX-I7, NT-I7IL-7R agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04042116Ib/IIRecurrent clear cell ovarian cancer, no prior VEGFR tyrosine kinase inhibitor (Phase II)LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid TumorCA, CO, FL, MA, NY, NC, OH, OK, PA, TN, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LucitanibVEGFR/FGFR dual kinase inhibitor E-3810VEGFR and FGFR kinase inhibitorClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03586661IbRecurrent high grade serous ovarian cancer; BRCA MUT patients must have progression after PARP inhibitor maintenance therapy (in expansion)A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CopanlisibBAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitorApproved in Other Cancers
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT03695380IbPlatinum sensitive BRCA WT ovarian cancer (≤ 2 prior platinum therapies) (in expansion)A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian CancerCA, FL, MD, MO, NY, TN, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
CobimetinibXL518, GDC-0973, CotellicMEK1 inhibitorApproved in Other Cancers
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT03725436IbAdvanced solid tumors that are TP53 WT with MDM2 AMP or MDM4 AMP (in expansion)A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast CancerTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ALRN-6924MDM2/MDMX inhibitor ALRN-6924MDM2 and MDMX inhibitorClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03872947IbPlatinum sensitive or partially sensitive ovarian cancer with no prior gemcitabineA Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid TumorsAZ, CA, LA, NJ, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
TRK-950monoclonal antibody TRK-950Undisclosed mechanismClinical Trials
NCT03842228IbAdvanced solid tumors with alterations in ARID1A, ATM, ATRX, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, MRE11A, MSH2, PALB2, PARP1, PIK3CA (E542, E545 or H1047), POLD1, PP2R2A, PTEN, RAD51B, RAD51C, RAD51D, RAD54L or XRCC2 (in expansion)A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid TumorsCO, MA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CopanlisibBAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitorApproved in Other Cancers
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03593226I/IIaAdvanced solid tumors - intratumoral injection (Phase II)A Phase I/IIA, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid TumoursCA, ORView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AGI-134αGal immunotherapyAnti-tumor immune response
NCT04130516I/IIaAdvanced solid tumors (Phase II)A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without PembrolizumabCA, CT, MA, NM, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LNS8801G protein-coupled estrogen receptor agonist LNS8801GPER agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT02484404I/IIRecurrent ovarian cancer (Phase II)Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CediranibRecentin, Cediranib maleate, AZD2171VEGFR1-3 kinase inhibitor
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03400332I/IIAdvanced solid tumors (Phase II)A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersAR, MD, NJ, NY, OK, PA, TX, UTView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
HuMax-IL8MDX 018, anti-IL-8 monoclonal antibody HuMax-IL8, BMS-986253IL-8 antagonistClinical Trials
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03157128I/IIAdvanced solid tumors with RET alterations (Phase II)A Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)AZ, CA, CO, CT, DC, FL, GA, IL, LA, MD, MA, MI, MN, MO, NV, NY, NC, OH, OR, PA, TN, TX, UT, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
SelpercatinibLOXO-292, RET kinase inhibitor LOXO-292, RetevmoRET-kinase inhibitorApproved in Other Cancers
NCT03767348I/IIAdvanced solid tumor with high MSI or dMMR - intratumoral injection (Phase II)An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid TumorsAZ, CA, FL, IA, KY, NJ, NY, NC, OH, PA, SC, TN, UT, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RP1oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virusInduces immune response and tumor cell lysisClinical Trials
NCT03416335I/IIAdvanced solid tumors (Phase II)A First-in-Human Phase 1/2 Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, Administered as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Advanced Solid TumorsNC, PA, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DSP-0509toll-like receptor 7 agonist DSP-0509TLR7 agonist and immune cell activatorClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03997968I/IIRecurrent ovarian cancer with prior PARP inhibitorA Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid TumorsAZ, CA, CO, FL, MA, MI, MN, NJ, NY, OK, PA, TN, TX, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CYT-0851RAD51 inhibitor
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
NCT04021043I/IIAdvanced solid tumors (Phase II)Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid MalignanciesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986156GITR (glucocorticoid-induced TNFR) agonistClinical Trials
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyRadiotherapy, Irradiation
NCT04317105I/IIAdvanced solid tumors with PIK3CA mutations (E542, E545, or H1047) or PTEN mutations (Phase II)A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients With Advanced Solid TumorsMA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CopanlisibBAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitorApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03093116I/IIAdvanced solid tumors with ALK, ROS1 or NTRK1-3 alterations (Phase II)A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)CA, CO, DC, FL, GA, IL, MD, MA, MI, MN, MO, NJ, NY, OH, PA, TX, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RepotrectinibALK/ROS1/NTRK/SRC multi-kinase inhibitor TPX-0005, TPX-0005ALK, ROS1, NTRK1-3, SRC and FAK kinase inhibitorClinical Trials
NCT02503423I/IIAdvanced solid tumors with oncogenic activation of the NF-κB pathway or amplification of c-IAP1 or c-IAP2 (Phase II)Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and LymphomasAL, CA, CT, GA, IL, MD, MA, MI, NH, NJ, NY, NC, OH, OK, OR, PA, SC, TN, TX, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TolinapantXIAP/cIAP1 antagonist ASTX660, ASTX660IAP antagonistClinical Trials
NCT03175224I/IIAdvanced solid tumors with MET AMP or MET gene fusions (Phase II)Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsAZ, CA, DE, FL, LA, MD, MA, MN, MO, NC, OH, PA, SC, TN, TX, UT, WA, WV, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BozitinibAPL-101, CBT-101, Vebreltinibc-Met kinase inhibitorClinical Trials
NCT04590326I/IIRecurrent ovarian cancerPhase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3)FL, IL, MA, MI, NY, OH, WAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Cemiplimabanti-PD-1 monoclonal antibody REGN2810, REGN2810, LibtayoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
REGN4018anti-MUC16/CD3 bispecific antibody REGN4018Re-directs T cells to attack MUC16 (CA125)+ tumor cellsClinical Trials
REGN5668Stimulates CD28 to increase T cell activation and immune response against MUC16 (CA125) expressing tumor cellsClinical Trials
NCT03037385I/IIAdvanced solid tumors with a RET alteration (Phase II)A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid TumorsAZ, CA, CO, DC, FL, MD, MA, MI, MN, MO, NY, OR, PA, TX, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PralsetinibBLU-667RET-kinase inhibitorApproved in Other Cancers
NCT03573544I/IIAdvanced Globo H+ solid tumors (Phase II)A Phase I/II, Open-Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.CA, NJ, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OBI-888anti-globo H monoclonal antibody OBI-888Immune response against cancer expressing Globo HClinical Trials
NCT04761198I/IIRecurrent high grade serous or endometrioid ovarian cancer or advanced solid tumors with high TMB that are MS-StableA Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors (ACTIVATE)AZ, CA, FL, MA, MI, MN, NY, NC, OK, TN, TX, UT, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
EtigilimabOMP-313M32, anti-TIGIT OMP-313M32Blocks TIGIT binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04907968I/IIPlatinum sensitive ovarian cancerAn Open-label, Multicenter, Dose Escalation and Expansion Modular, Umbrella Master Study of Upifitamab Rilsodotin in Combination With Other Agent(s) In Participants With High-grade Serous Ovarian Cancer (UPGRADE)MA, MI, SCView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
Upifitamab rilsodotinXMT-1536, UpRiADC: anti-NaPi2b + microtubule destabilizer (auristatin F-HPA)Clinical Trials
NCT04370587I/IIAdvanced solid tumors with cutaneous or subcutaneous lesions - intratumoral injection (Phase II)A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 When Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid TumorsAZ, MA, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
T3011oncolytic HSV-1-expressing IL-12 and anti-PD-1 antibody T3011Induces immune response and tumor cell lysisClinical Trials
NCT01434316IAdvanced solid tumors including those with BRCA1/2 mutations (in expansion)Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid TumorsMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DinaciclibCDK inhibitor SCH 727965, SCH 727965CDK1, 2, 5, 9 inhibitorClinical Trials
VeliparibABT-888PARP inhibitorClinical Trials
NCT02264678IPlatinum sensitive ovarian cancer that is BRCA MUT or with RAD51C/D mut or HRD+ with prior progression on a PARP inhibitor, no prior ATR inhibitorA Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies.CA, MD, MA, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT01543763IAdvanced solid tumors (in ovarian expansion)Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid TumorsCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbexinostatPCI-24781, HDAC inhibitor CRA-024781HDAC inhibitorClinical Trials
PazopanibVotrientMulti-targeted RTK inhibitor
NCT02720068IAdvanced solid tumors (in expansion)A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab With or Without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects With Advanced Solid TumorsCA, CO, MN, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Favezelimabanti-LAG3 monoclonal antibody MK-4280, MK-4280Blocks LAG-3 inhibition of T cellsClinical Trials
IrinotecanCampothecin-11, Campto, CamptosarTopoisomerase I inhibitorNCCN Guidelines for Ovarian Cancer
LenvatinibMK-7902, Lenvima, ER-203492-00, E7080Multi-targeted RTK inhibitorApproved in Other Cancers
OxaliplatinOHP, Eloxatine, Dacplat, Dacotin, EloxatinDNA damaging agent
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT01376505IAdvanced solid tumors (in ovarian expansion)Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid TumorsOHView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MVF-HER-2(597-626)-MVF-HER-2 (266-296) peptide vaccineB-VaxxImmune response against cancer expressing HER2Clinical Trials
NCT03023319IAdvanced solid tumors (in expansion)Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid TumorsGAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BosutinibSKI-606, BosulifAbl and src family kinase inhibitorApproved in Other Cancers
PemetrexedPemetrexed disodium, AlimtaDHFR and Thymidylate synthase inhibitorNCCN Guidelines for Ovarian Cancer
NCT03054298IRecurrent or persistent serous ovarian cancerPhase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing CancersPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
huCART-meso cellsImmune response against cancer expressing mesothelinClinical Trials
NCT03386526IAdvanced solid tumors (in expansion)A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as A Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic MalignanciesMI, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
APG-1387SMAC mimetic and IAP antagonistClinical Trials
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03059823IAdvanced solid tumors (in expansion)A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid TumorsTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RetifanlimabMGA012, anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1/2 inhibition of T cellsClinical Trials
NCT03508570IRecurrent ovarian cancer with disease in the peritoneal cavity or retroperitoneal lymph nodes (in ovarian expansion)Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic CancersTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03585764IRecurrent or persistent FRalpha+ high grade serous ovarian cancerPhase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerPAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
MOv19-BBz CAR TImmune response against cancer expressing folate receptorClinical Trials
NCT03530397IAdvanced solid tumors (in expansion)A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors.MI, NY, NC, RI, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
MEDI5752anti-PD-1/CTLA-4 bispecific antibody MEDI5752Blocks PD-1 and CTLA-4 inhibition of T cellsClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PemetrexedPemetrexed disodium, AlimtaDHFR and Thymidylate synthase inhibitorNCCN Guidelines for Ovarian Cancer
NCT03934814IAdvanced solid tumors (in ovarian expansion)A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and LymphomaAL, AZ, CA, CT, FL, IN, MI, MN, NJ, NY, TN, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LemzoparlimabTJC4, TJ011133Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosisClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03968406IRecurrent ovarian cancer (amenable to radiation therapy) - without ascitesPhase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic CancersTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Radiation TherapyRadiotherapy, Irradiation
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
NCT04053673IAdvanced solid tumors with PARP7 AMP (in expansion)A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid TumorsCO, CT, FL, MA, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RBN-2397PARP7 inhibitorClinical Trials
NCT04092270IRecurrent ovarian cancer (inc expansion)A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)MA, NJ, NY, OK, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
NedisertibM3814, DNA-PK inhibitor MSC2490484A, PeposertibDNA-PK inhibitorClinical Trials
NCT04149145IRecurrent ovarian cancer with progression on prior PARP inhibitor (inc expansion)Trial of M4344 and Niraparib in Patients With PARP Resistant Recurrent Ovarian CancerALView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
M4344VX-803ATR kinase inhibitorClinical Trials
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT04182516IAdvanced solid tumors (inc ovarian expansion)A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients With Selected Advanced/Metastatic Solid TumorsTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NMS-03305293PARP inhibitorClinical Trials
NCT03454451IAdvanced solid tumors (in expansion)A Phase 1/1b Multicenter Study to Evaluate the Humanized Anti-CD73 Antibody, CPI-006, as a Single Agent or in Combination With Ciforadenant, With Pembrolizumab, and With Ciforadenant Plus Pembrolizumab in Adult Subjects With Advanced CancersAZ, CA, CT, FL, IL, MD, MA, NV, NY, NC, OH, OK, PA, SC, TN, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Ciforadenantadenosine-A2A receptor antagonist CPI-444, CPI-444Blocks adenosine A2a receptor inhibition of T cellsClinical Trials
CPI-006anti-CD73 monoclonal antibody CPI-006, CPX-006Blocks Ecto-5-nucleotidase (CD73) inhibition of T cellsClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04293094IAdvanced solid tumors with mutation in TP53 (inc ovarian expansion)A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid TumorsCA, IN, MN, MO, NY, NC, OK, OR, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AMG 650KIF18A inhibitorClinical Trials
NCT04315233IRecurrent serous ovarian cancerA Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE)UTView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BelinostatPXD101HDAC inhibitorApproved in Other Cancers
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitorApproved in Other Cancers
NCT04329494IRecurrent ovarian cancer (with peritoneal disease)Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC)CA, FL, NYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
Doxorubicin14-Hydroxydaunomycin, Hydroxyl-DaunorubicinTopoisomerase II inhibitorApproved in Other Cancers
PIPACpressurized intraperitoneal aerosol chemotherapyClinical Trials
NCT04608409IPartially platinum sensitive, platinum resistant or refractory ovarian cancerA Phase I Dose-Escalation Study on the Safety of Lapatinib With Dose-Dense Paclitaxel in Patients With Platinum-Resistant Ovarian CancerKYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LapatinibGW2016, GSK572016, lapatinib ditosylate, TykerbEGFR and HER2 kinase inhibitorApproved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04611139ISmall cell of hypercalcemic type (SCCOHT), clear cell, or endometrioid ovarian cancer with SMARCA4 or ARID1A mutationsPilot Feasibility and Efficacy Trial of a Novel Reversible LSD1 Inhibitor SP-2577 (Seclidemstat) Plus Pembrolizumab in Select SWI/SNF-mutant Gynecologic CancersAZView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
SeclidemstatLSD1 inhibitor SP-2577, SP-2577LSD1 inhibitorClinical Trials
NCT04044859IAdvanced MAGE-A4+ solid tumors (in expansion)A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive TumorsMA, MO, NC, OK, PA, TN, TX, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ADP-A2M4CD8SPEAR T-cell ADP-A2M4CD8, autologous genetically-modified MAGE-A4 C1032 CD8alpha T cellsImmune response against cancer expressing MAGE-A4Clinical Trials
NCT04673448IRecurrent BRCA MUT ovarian cancerPhase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary CancerWAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DostarlimabTSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT04669899IAdvanced solid tumors (inc ovarian expansion)Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor MalignanciesCA, FL, MI, NC, SC, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
JTX-8064Blocks ILT4 inhibition of immune cellsClinical Trials
Pimivalimabanti-PD-1 monoclonal antibody JTX-4014, JTX-4014Blocks PD-L1/2 inhibition of T cellsClinical Trials
NCT04703920IRecurrent high grade serous ovarian cancerA Phase 1 Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian CancerMIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BelinostatPXD101HDAC inhibitorApproved in Other Cancers
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
NCT04707248IRecurrent ovarian cancer (inc expansion)Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsFL, OK, TNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DS-6000aADC: anti-CDH6 + topoisomerase I inhibitor (Dxd)Clinical Trials
NCT04711161IRecurrent ovarian cancer (inc expansion)Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
GRN-300SIK2/3 inhibitorClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04706962IAdvanced solid tumors (inc ovarian expansion)A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients With Advanced Solid Tumors and Expansion in Patients With Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer, and Pancreatic CancerCA, MI, PA, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TH1902ADC: anti-SORT1 + microtubule stabilizer/mitotic inhibitor (docetaxel)Clinical Trials
NCT05057715IPersistent or recurrent serous ovarian cancerPhase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian CancerContact research study staffView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
huCART-meso cellsImmune response against cancer expressing mesothelinClinical Trials
VCN-01PH20 hyaluronidase-expressing adenovirus VCN-01Induces immune response and tumor cell lysisClinical Trials
NCT03748186IRecurrent high grade serous ovarian cancer (in ovarian expansion)A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial CancersAZ, CO, CT, FL, GA, IL, MD, MN, NV, NY, NC, OH, PA, SC, TN, VA, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
STRO-002ADC: anti-FOLR1 + microtubule destabilizer (SC209)Clinical Trials
NCT04630769IRecurrent ovarian cancer - intraperitoneal infusionIntraperitoneal FATE FT516 and Interleukin-2 (IL-2) With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerMNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinProleukinIL-2 receptor agonistApproved in Other Cancers
Enoblituzumabmab MGA271, MGA271Immune response against cancer expressing B7H3Clinical Trials
FT516iPSC-derived non-cleavable CD16 (hnCD16) Fc receptor expressing NK cells FT516Anti-tumor immune responseClinical Trials
NCT04847063IOvarian cancer with peritoneal disease - expected to undergo complete cytoreductionIndividualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma HistologiesMDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
Doxorubicin14-Hydroxydaunomycin, Hydroxyl-DaunorubicinTopoisomerase II inhibitorApproved in Other Cancers
FloxuridineWR-138720, 5-FUDRRNA and DNA synthesis inhibitor
HIPECHyperthermic Intraperitoneal ChemotherapyNCCN Guidelines for Ovarian Cancer
Mitomycin CAmetycine, MITO-C, Mitocin, Mitolem, Mitosol, Mitozytrex, Mutamycin, NCI-C04706DNA synthesis inhibitorApproved in Other Cancers
OxaliplatinOHP, Eloxatine, Dacplat, Dacotin, EloxatinDNA damaging agent
SurgeryClinical Trials

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at patientsupport@clearityfoundation.org.